Last updated: February 19, 2026
This analysis examines the patent litigation between Eli Lilly and Company and Apotex Inc. concerning the blockbuster drug Trulicity (dulaglutide). The core of the dispute involves allegations of patent infringement and invalidity related to Lilly's U.S. Patent No. 7,977,334.
What Patents Are in Dispute?
The central patent at issue is U.S. Patent No. 7,977,334, titled "GLUCAGON-LIKE PEPTIDE-1 (GLP-1) DERIVATIVES." This patent covers GLP-1 receptor agonists, including dulaglutide, the active pharmaceutical ingredient in Trulicity [1]. Lilly alleges that Apotex's proposed generic dulaglutide product infringes claims within this patent [2].
What Are the Key Allegations?
Eli Lilly alleges that Apotex's Abbreviated New Drug Application (ANDA) for its generic dulaglutide product infringes U.S. Patent No. 7,977,334. Lilly asserts that Apotex's product falls within the scope of one or more claims of the '334 patent.
Apotex, in turn, argues that the asserted claims of the '334 patent are invalid. Their invalidity arguments typically center on prior art, asserting that the claimed invention was not novel or was obvious at the time of filing the patent application [3].
What Is the Status of the Litigation?
This litigation is part of an ongoing Hatch-Waxman Act Paragraph IV certification dispute. Apotex, as a generic drug manufacturer, notified Lilly that its proposed generic product would not infringe the '334 patent or that the patent is invalid [4]. Lilly then initiated an infringement lawsuit.
The case has progressed through various stages, including discovery and claim construction. The outcome of claim construction, where the court defines the meaning and scope of patent claims, is critical in determining infringement.
What Are the Key Legal Arguments?
Infringement
Lilly's infringement argument focuses on demonstrating that Apotex's generic dulaglutide product practices the invention as claimed in U.S. Patent No. 7,977,334. This requires showing that Apotex's product contains the specific chemical structure or exhibits the therapeutic properties covered by the patent claims. Lilly typically presents evidence from its own studies, Apotex's ANDA filings, and potentially expert testimony to support its infringement allegations [2].
Invalidity
Apotex's invalidity defense typically involves challenging the '334 patent based on:
- Anticipation (35 U.S.C. § 102): Arguing that the claimed invention is not new because it was previously known or described in the prior art [3].
- Obviousness (35 U.S.C. § 103): Asserting that the claimed invention would have been obvious to a person of ordinary skill in the art at the time the patent was filed, given the existing prior art [3].
Apotex's invalidity arguments often involve identifying specific prior art references (e.g., scientific publications, earlier patents) that they contend disclose or suggest the claimed invention.
What Is the Timeline of Key Events?
- Patent Issuance: U.S. Patent No. 7,977,334 issued on July 12, 2011 [1].
- ANDA Filing: Apotex filed its ANDA for generic dulaglutide.
- Notice of Paragraph IV Certification: Apotex notified Lilly of its intent to market a generic version, challenging the '334 patent.
- Litigation Commencement: Eli Lilly filed its patent infringement lawsuit against Apotex Inc. in the U.S. District Court for the Southern District of Indiana on February 19, 2016 [5].
- Claim Construction Hearings: The court held Markman hearings to construe the claims of the '334 patent.
- Potential Settlement or Trial: Depending on the court's rulings on claim construction, infringement, and validity, the case may proceed to trial or be resolved through settlement.
What Are the Potential Business Implications?
The outcome of this litigation has significant financial implications for both Eli Lilly and Apotex.
- For Eli Lilly: A favorable ruling upholding the validity and infringement of the '334 patent would extend Trulicity's market exclusivity and protect its substantial revenue stream. Trulicity generated approximately $6.5 billion in sales in 2022 [6]. A loss would open the market to generic competition, leading to a rapid decline in Trulicity's sales.
- For Apotex: A successful challenge to the '334 patent would allow Apotex to launch its generic dulaglutide product, capturing a share of the lucrative GLP-1 receptor agonist market. Generic competition typically leads to price reductions of 30-50% or more for branded drugs.
What is the Market Landscape for Dulaglutide?
Trulicity is a leading GLP-1 receptor agonist used for the treatment of type 2 diabetes. The market for GLP-1 receptor agonists is substantial and growing, driven by the increasing prevalence of diabetes and obesity. Competitors in this space include Novo Nordisk's Ozempic (semaglutide) and Victoza (liraglutide), and AstraZeneca's Farxiga (dapagliflozin), although Farxiga is an SGLT2 inhibitor and not a direct GLP-1 competitor. The introduction of generic dulaglutide would introduce significant price pressure into this segment [7].
What is the Scope of the '334 Patent Claims?
The '334 patent contains multiple claims directed to GLP-1 receptor agonists. For instance, Claim 1 of the '334 patent, as cited in public filings, generally claims a modified human GLP-1 (7-37) sequence [8]. The specific wording of the asserted claims and their construction by the court are paramount to determining infringement. Lilly asserts claims that it believes cover dulaglutide directly or indirectly.
How Has the Court Addressed Claim Construction?
Claim construction in patent litigation is a critical phase. The court interprets the meaning of disputed claim terms. The Federal Circuit has established that claim construction is a matter of law [9]. The specific interpretations of key terms in the '334 patent by the District Court and potentially the Court of Appeals for the Federal Circuit will dictate whether Apotex's product falls within the patented claims. This process involves analyzing the patent specification, the prosecution history, and potentially expert testimony [10].
What Are the Potential Outcomes?
- Infringement and Validity Upheld: The court finds that Apotex infringes the '334 patent and that the patent is valid. This would prevent Apotex from launching its generic product until the patent expires or is otherwise invalidated.
- No Infringement: The court finds that Apotex's product does not infringe the '334 patent, even if the patent is valid. This would allow Apotex to launch its generic product.
- Patent Invalidity: The court finds that the asserted claims of the '334 patent are invalid. This would prevent Lilly from asserting these claims against Apotex and would allow Apotex to launch its generic product.
- Settlement: The parties may reach a settlement agreement, which could involve a licensing agreement for Apotex to launch a generic product after a certain date or with specific terms.
Key Takeaways
- The litigation centers on U.S. Patent No. 7,977,334, which covers GLP-1 receptor agonists including dulaglutide, the active ingredient in Eli Lilly's Trulicity.
- Eli Lilly alleges patent infringement by Apotex Inc.'s proposed generic dulaglutide product.
- Apotex contends that the asserted claims of the '334 patent are invalid, citing prior art.
- The case is a Paragraph IV certification dispute under the Hatch-Waxman Act, impacting market exclusivity for Trulicity.
- The outcome will significantly influence the competitive landscape and pricing for GLP-1 receptor agonists, a high-value pharmaceutical market.
Frequently Asked Questions
- What specific claims of U.S. Patent No. 7,977,334 are asserted by Eli Lilly against Apotex?
- What prior art references are being used by Apotex to challenge the validity of the '334 patent?
- Has a final court decision been issued regarding the infringement or validity of the '334 patent in this case?
- What is the estimated market size for dulaglutide globally?
- Does the litigation impact Eli Lilly's ongoing sales of Trulicity during the pendency of the lawsuit?
Citations
[1] U.S. Patent No. 7,977,334. (2011). GLUCAGON-LIKE PEPTIDE-1 (GLP-1) DERIVATIVES. Eli Lilly and Company.
[2] Eli Lilly and Company v. Apotex Inc., No. 1:16-cv-001512 (S.D. Ind. filed Feb. 19, 2016).
[3] 35 U.S.C. § 102 (2012).
[4] 35 U.S.C. § 271(e)(2) (2012).
[5] Complaint for Patent Infringement, Eli Lilly and Company v. Apotex Inc., No. 1:16-cv-001512 (S.D. Ind. filed Feb. 19, 2016).
[6] Eli Lilly and Company. (2023). Form 10-K for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.
[7] Global GLP-1 Receptor Agonists Market Size, Share & Industry Trends Report By Drug Type, By Disease Type, By Distribution Channel, By Regional Outlook And Forecast, 2022-2028. (2022). Markntimes. Retrieved from https://www.markntimes.com/global-glp-1-receptor-agonists-market-size-share-industry-trends-report-by-drug-type-by-disease-type-by-distribution-channel-by-regional-outlook-and-forecast-2022-2028/
[8] U.S. Patent No. 7,977,334, col. 12 l. 65 – col. 16 l. 38 (filed Jan. 3, 2006).
[9] Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996).
[10] Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005).
